Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 115

Similar articles for PubMed (Select 21775738)

1.

Immune thrombocytopenic purpura in a patient with multiple sclerosis treated with natalizumab.

Stosic M, De Jesus P, McCarthy J, Hutton G, Rivera V.

Neurology. 2011 Aug 2;77(5):505-7. doi: 10.1212/WNL.0b013e318227b23f. Epub 2011 Jul 20. No abstract available.

PMID:
21775738
2.

B-cell depletion in immune thrombocytopenia.

Psaila B, Cooper N.

Lancet. 2015 Apr 25;385(9978):1599-601. doi: 10.1016/S0140-6736(14)61930-9. Epub 2015 Feb 5. No abstract available.

PMID:
25662418
3.

Author response.

Fox RJ.

Neurology. 2014 Nov 25;83(22):2100. No abstract available.

PMID:
25574542
4.

MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study.

Svenningsson A, Sundstrom P, Salzer J, Vagberg M.

Neurology. 2014 Nov 25;83(22):2099-100. doi: 10.1212/01.wnl.0000457455.74798.9a. No abstract available. Erratum in: Neurology. 2015 Feb 24;84(8):862.

PMID:
25422402
5.

Diagnosis and trials of clinically isolated syndrome.

Montalban X, Sastre-Garriga J.

Lancet Neurol. 2014 Oct;13(10):962-3. doi: 10.1016/S1474-4422(14)70202-9. Epub 2014 Sep 2. No abstract available.

PMID:
25192850
6.

[Teriflunomide (Aubagio). New treatment for multiple sclerosis].

Sabourin G.

Perspect Infirm. 2014 May-Jun;11(3):56. French. No abstract available.

PMID:
24855766
7.

Natalizumab discontinuation in the increasing complexity of multiple sclerosis therapy.

Sormani MP, De Stefano N.

Neurology. 2014 Apr 29;82(17):1484-5. doi: 10.1212/WNL.0000000000000369. Epub 2014 Mar 28. No abstract available.

PMID:
24682968
8.

Immune thrombocytopenic purpura: major progress in knowledge of the pathophysiology and the therapeutic strategy, but still a lot of issues.

Godeau B.

Presse Med. 2014 Apr;43(4 Pt 2):e47-8. doi: 10.1016/j.lpm.2014.02.010. Epub 2014 Mar 26. Review. No abstract available.

PMID:
24680419
9.

[Neuroinflammatory diseases with a focus on multiple sclerosis - an overview].

Hohlfeld R.

Drug Res (Stuttg). 2013 Nov;63 Suppl 1:S3-4. doi: 10.1055/s-0033-1346704. Epub 2013 Nov 15. German. No abstract available.

10.

Rasmussen encephalitis treated with natalizumab.

Bittner S, Simon OJ, Göbel K, Bien CG, Meuth SG, Wiendl H.

Neurology. 2013 Jul 23;81(4):395-7. doi: 10.1212/WNL.0b013e31829c5ceb. Epub 2013 Jun 21. No abstract available.

PMID:
23794679
11.

[Reply to commentary on "Rituximab in thrombocytopenic purpura..."].

Zambrano-Velarde MA, de la O-Peña D, Chávez-Peña Q, Bedolla-Barajas M.

Rev Med Inst Mex Seguro Soc. 2012 Jul-Aug;50(4):353-4. Spanish. No abstract available.

PMID:
23234735
12.

[Commentary on "Rituximab in thrombocytopenic purpura..."].

García-Álvarez JL.

Rev Med Inst Mex Seguro Soc. 2012 Jul-Aug;50(4):351-2. Spanish. No abstract available.

PMID:
23234734
13.

Are 25 antibodies better than 1?

Cuker A.

Blood. 2012 Nov 1;120(18):3627-8. doi: 10.1182/blood-2012-09-452771. No abstract available.

14.

Risk stratification and patient counseling for natalizumab in multiple sclerosis.

Fox RJ, Rudick RA.

Neurology. 2012 Feb 7;78(6):436-7. doi: 10.1212/WNL.0b013e318245d2d0. Epub 2012 Jan 25. No abstract available.

PMID:
22282644
15.

CD70: probably being a therapeutic target in human multiple sclerosis.

Wangdong X.

Rheumatol Int. 2013 Mar;33(3):815. doi: 10.1007/s00296-011-2112-7. Epub 2011 Dec 8. No abstract available.

PMID:
22159875
16.

Severe acute autoimmune hepatitis after natalizumab treatment.

Lisotti A, Azzaroli F, Brillanti S, Mazzella G.

Dig Liver Dis. 2012 Apr;44(4):356-7. doi: 10.1016/j.dld.2011.11.003. Epub 2011 Dec 11. No abstract available.

PMID:
22154948
17.

Natalizumab discontinuation: an increasingly tricky proposition.

West TW, Killestein J, Fox RJ.

Eur J Neurol. 2012 May;19(5):663-4. doi: 10.1111/j.1468-1331.2011.03574.x. Epub 2011 Nov 7. No abstract available.

PMID:
22054207
18.

Giant cell hepatitis and immune thrombocytopenic purpura: reversal of liver failure with rituximab therapy.

Shores D, Kobak G, Pegram LD, Whitington PF, Shneider BL.

J Pediatr Gastroenterol Nutr. 2012 Oct;55(4):e128-30. No abstract available.

PMID:
21921813
19.

Multiple sclerosis treatment: First oral drug, new antibody therapies.

Frohman T, Orchard M, Hardeman P, O'Donoghue DL.

JAAPA. 2011 Aug;24(8):54, 56. No abstract available.

PMID:
21850921
20.

Can we kill an extra bird with the same stone?

Laroni A, Giacosa A, Uccelli A, Mancardi GL.

Inflamm Bowel Dis. 2011 Sep;17(9):E124-5. doi: 10.1002/ibd.21802. Epub 2011 Jun 24. No abstract available.

PMID:
21710537
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk